StoneX Group’s Cidara Therapeutics CDTX Stock Holding History

StoneX Group’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-750	Closed	-$11.3K	–	482
2022 Q4	$11.3K	Buy	+750	New	+$8.95K	﹤0.01%	448

Other funds holding CDTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

StoneX Group's CDTX Position: Q1 2023 in Review

StoneX Group sold out of Cidara Therapeutics (CDTX) in Q1 2023, closing a stake of 750 shares — an estimated $11.3K sold.

StoneX Group first reported a position in CDTX in Q4 2022 and held it in 1 quarter. The position peaked at $11.3K in Q4 2022. 54 funds tracked by Wall St. Rank hold CDTX as of Q1 2023.

StoneX Group reported no remaining Cidara Therapeutics position as of Q1 2023 after selling out during the quarter.
StoneX Group sold 750 Cidara Therapeutics shares in Q1 2023, an estimated $11.3K.
StoneX Group first reported a position in Cidara Therapeutics in Q4 2022 and held it in 1 quarter.
StoneX Group's Cidara Therapeutics position peaked at $11.3K in Q4 2022.
54 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.